Literature DB >> 8704290

Functional imaging predicts cognitive decline in Alzheimer's disease.

W J Jagust1, M N Haan, J L Eberling, N Wolfe, B R Reed.   

Abstract

Eighteen patients with Alzheimer's disease were studied with positron emission tomographic measurements of regional cerebral metabolism of glucose. All patients were initially diagnosed and evaluated, underwent positron emission tomography, and then were followed with annual reevaluations, at which time the Mini-Mental State Examination (MMSE) was performed. Patients were followed for an average of 2.5 years, and the rate of cognitive decline was calculated by determining the rate of change in the MMSE score defined as the MMSE score at the initial evaluation minus the MMSE score at the last examination, divided by the number of months between testing. The regional cerebral metabolic rates for glucose determined at the time of the first MMSE were then regressed on these changes in scores. Results showed that glucose metabolic rates in posterior temporal and primary visual cortex regions were significantly correlated with the subsequent rate of cognitive deterioration. These associations were not confounded by age, length of follow-up, baseline MMSE score, or education. Stratification on gender suggested that these associations were much stronger in women than in men. These results replicate previous findings showing that functional brain imaging is predictive of the rate of cognitive decline in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8704290     DOI: 10.1111/jon199663156

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  13 in total

Review 1.  Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease.

Authors:  F Portet; P J Ousset; P J Visser; G B Frisoni; F Nobili; Ph Scheltens; B Vellas; J Touchon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03-20       Impact factor: 10.154

2.  Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events.

Authors:  R J Haier; K Head; E Head; I T Lott
Journal:  Neuroimage       Date:  2007-10-12       Impact factor: 6.556

Review 3.  Molecular neuroimaging in Alzheimer's disease.

Authors:  William Jagust
Journal:  NeuroRx       Date:  2004-04

4.  Evidence for ordering of Alzheimer disease biomarkers.

Authors:  Clifford R Jack; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Paul S Aisen; John Q Trojanowski; Leslie M Shaw; Matthew A Bernstein; Ronald C Petersen; Michael W Weiner; David S Knopman
Journal:  Arch Neurol       Date:  2011-08-08

5.  Greater cortical thinning in normal older adults predicts later cognitive impairment.

Authors:  Jennifer Pacheco; Joshua O Goh; Michael A Kraut; Luigi Ferrucci; Susan M Resnick
Journal:  Neurobiol Aging       Date:  2014-09-06       Impact factor: 4.673

6.  Method to correlate 1H MRSI and 18FDG-PET.

Authors:  J O'Neill; J L Eberling; N Schuff; W Jagust; B Reed; G Soto; F Ezekiel; G Klein; M W Weiner
Journal:  Magn Reson Med       Date:  2000-02       Impact factor: 4.668

Review 7.  Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease.

Authors:  Bradford C Dickerson; Reisa A Sperling
Journal:  NeuroRx       Date:  2005-04

8.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2010-01       Impact factor: 44.182

9.  Dynamics of gray matter loss in Alzheimer's disease.

Authors:  Paul M Thompson; Kiralee M Hayashi; Greig de Zubicaray; Andrew L Janke; Stephen E Rose; James Semple; David Herman; Michael S Hong; Stephanie S Dittmer; David M Doddrell; Arthur W Toga
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

10.  Evidence for brain glucose dysregulation in Alzheimer's disease.

Authors:  Yang An; Vijay R Varma; Sudhir Varma; Ramon Casanova; Eric Dammer; Olga Pletnikova; Chee W Chia; Josephine M Egan; Luigi Ferrucci; Juan Troncoso; Allan I Levey; James Lah; Nicholas T Seyfried; Cristina Legido-Quigley; Richard O'Brien; Madhav Thambisetty
Journal:  Alzheimers Dement       Date:  2017-10-19       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.